SironRX Completes Enrollment in Phase I Clinical Trial

SironRX Completes Enrollment in Phase I Clinical Trial

04/17/2013

Cleveland, OH--SironRX is pleased to announce the completion of enrollment in Cohort 1 of its clinical trial to test its lead compound, JVS-100, in wound healing. Cohort 2 is being actively enrolled.
The clinical trial, designed to evaluate the safety and efficacy of JVS-100 in reducing scar formation and improving wound healing in patients receiving sternotomy incisions, is a placebo-controlled, randomized dose escalation double-blind clinical study.
JVS-100 encodes Stromal cell-Derived Factor 1 (SDF-1) an important natural chemokine which repairs damaged tissue through recruitment of circulating stem cells to the site of injury, prevents ongoing cell death and restores localized blood flow. This regenerative therapy has demonstrated the ability to reduce scarring and accelerate dermal wound healing after delivery to damaged skin in multiple preclinical investigations.
Patients in Cohort I were enrolled at University of Utah Hospital, Montefiore Medical Center and Summa Health Systems.  Several additional centers are joining the trial for enrollment in Cohorts II and III.
Dr. Amit Patel, Director of Cardiovascular Regenerative Medicine and Associate Professor of Surgery at the University of Utah treated the first patient in the trial. “Current wound healing treatments are focused largely on ensuring the incision site retains a certain set of environmental conditions to aid healing. This treatment is different in that it is aimed directly at triggering the body’s own repair mechanism, so rather than impacting only one element of the repair process, this therapy is enhancing the entire set of pathways. There are no other therapies existing today that do this.”
Dr. Robert Michler, of Montefiore Medical Center added, "We are excited and hopeful that the use of SDF-1, a novel regenerative medicine therapy, will promote faster wound healing and reduce scarring in our heart surgery patients. The applications for such a therapy would be widespread and includes the potential for healing hearts damaged by heart attacks.” Dr. Michler is Surgeon-in-Chief, Samuel I. Belkin Chair, Professor and Chairman, Department of Surgery and Professor and Chairman, Department of Cardiovascular and Thoracic Surgery, Montefiore Medical Center/Albert Einstein College of Medicine New York.
Dr. Marc Penn, founder of SironRX commented, "the clinical development of JVS-100 highlights the benefits and clinical translatability of defining the molecular mechanisms associated with stem cell based tissue repair.  Our bench and clinical work to date demonstrate that SDF-1, which is induced by JVS-100, is clearly central in the biology of tissue repair throughout the body.” Dr. Marc Penn is Director of Research, Summa Cardiovascular Institute, Summa Health System and Professor of Medicine and Integrative Medical Sciences at Northeast Ohio Medical University. 
SironRX President & CEO Evan Facher commented, "SironRX is committed to developing novel therapies that reduce scar formation and accelerate wound healing, both of which represent important unmet medical needs. Advancing to the next phase of this clinical trial with top-tier clinical centers is an milestone for the Company, its investors and partners. We are excited about the current study and also by the significant opportunity that extends well beyond it in the large dermal scar prevention and wound healing market.” Read more...

Find Out More About ESP

Staff Photo
Mike Bunker manages the Early Stage Partners investment in SironRX